Mengjie Shen

• Optimise lipid composition and formulation parameters to improve mRNA delivery efficiency, stability and safety
• Tune LNP design to influence biodistribution and enable more precise, cell-specific targeting
• Bridge discovery and clinical translation by aligning LNP design with scalability, manufacturability and regulatory requirements

3–4 speakers each briefly defend a different approach in this open debate. The audience votes on the most promising strategy.

• Lipid chemistry vs formulation tuning vs hybrid systems
• Passive biodistribution control vs active targeting (ligands, peptides, etc.)
• Incremental optimisation vs completely new delivery paradigms
• What actually translates in vivo vs what only works in preclinical models